Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q1 CY2025, with sales up 111% year on year to $586 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $540 million was less impressive, coming in 2.4% below expectations. Its non-GAAP profit of $0.30 per share was 32.2% above analysts’ consensus estimates.
Hims & Hers stock was trading lower but has since reversed and began trading higher after the company reported first-quarter earnings on Monday after the market closed.
Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 111% year on year to $586 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $540 million was less impressive, coming in 4.3% below expectations. Its GAAP profit of $0.20 per share was 66.4% above analysts’ consensus estimates.
Hims & Hers Health shares are trading marginally lower Monday morning. The company earlier appointed Nader Kabbani as its new Chief Operations Officer, ahead of Q1 results.
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas.
A nearly 20-year Amazon veteran, Nader Kabbani said he was drawn to Hims & Hers by its potential to expand access to fast, reliable, and high-quality care.
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity.
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance.
